Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORAvance Pharmacokinetics and Safety in Renal Impairment
NCT06157242Phase 1Completed
- Sponsor
- Qpex Biopharma
- Start
- Nov 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of xeruborbactam isoboxil in bacterial infection, sponsored by Qpex Biopharma. Primary endpoints: Incidence of Treatment Emergent Adverse Events at 10 days, Changes from Baseline in Safety Parameters at 10 days and 5 more. Started Nov 2024; status: completed.
02
Drugs
xeruborbactam isoboxil
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT06157242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06157242.